<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">08-PONE-RA-03968</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0002255</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Biochemistry</subject><subject>Cardiovascular Disorders</subject><subject>Cardiovascular Disorders/Coronary Artery Disease</subject><subject>Biochemistry</subject><subject>Cardiovascular Disorders</subject><subject>Cardiovascular Disorders/Coronary Artery Disease</subject></subj-group></article-categories><title-group><article-title>Elevated Expression of Phospholipid Transfer Protein in Bone Marrow Derived Cells Causes Atherosclerosis</article-title><alt-title alt-title-type="running-head">Macrophage PLT</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>van Haperen</surname><given-names>Rien</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Samyn</surname><given-names>Hannelore</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Moerland</surname><given-names>Matthijs</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>van Gent</surname><given-names>Teus</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Peeters</surname><given-names>Marian</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Grosveld</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>van Tol</surname><given-names>Arie</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>de Crom</surname><given-names>Rini</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Cell Biology and Genetics, Erasmus MC University Medical Center, Rotterdam, The Netherlands</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department of Vascular Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Williams</surname><given-names>R. Sanders S.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Duke University, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>m.decrom@erasmusmc.nl</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: FG Rd HS MM Tv MP Av Rv. Performed the experiments: Tv MP Rv. Analyzed the data: Tv Rv. Wrote the paper: FG Rd HS MM Tv MP Av Rv.</p></fn></author-notes><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>28</day><month>5</month><year>2008</year></pub-date><volume>3</volume><issue>5</issue><elocation-id>e2255</elocation-id><history><date date-type="received"><day>14</day><month>3</month><year>2008</year></date><date date-type="accepted"><day>25</day><month>3</month><year>2008</year></date></history><copyright-statement>van Haperen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2008</copyright-year><abstract><sec><title>Background</title><p>Phospholipid transfer protein (PLTP) is expressed by various cell types. In plasma, it is associated with high density lipoproteins (HDL). Elevated levels of PLTP in transgenic mice result in decreased HDL and increased atherosclerosis. PLTP is present in human atherosclerotic lesions, where it seems to be macrophage derived. The aim of the present study is to evaluate the atherogenic potential of macrophage derived PLTP.</p></sec><sec><title>Methods and Findings</title><p>Here we show that macrophages from human PLTP transgenic mice secrete active PLTP. Subsequently, we performed bone marrow transplantations using either wild type mice (PLTPwt/wt), hemizygous PLTP transgenic mice (huPLTPtg/wt) or homozygous PLTP transgenic mice (huPLTPtg/tg) as donors and low density lipoprotein receptor deficient mice (LDLR&#x02212;/&#x02212;) as acceptors, in order to establish the role of PLTP expressed by bone marrow derived cells in diet-induced atherogenesis. Atherosclerosis was increased in the huPLTPtg/wt&#x02192;LDLR&#x02212;/&#x02212; mice (2.3-fold) and even further in the huPLTPtg/tg&#x02192;LDLR&#x02212;/&#x02212; mice (4.5-fold) compared with the control PLTPwt/wt&#x02192;LDLR&#x02212;/&#x02212; mice (both P&#x0003c;0.001). Plasma PLTP activity levels and non-HDL cholesterol were increased and HDL cholesterol decreased compared with controls (all P&#x0003c;0.01). PLTP was present in atherosclerotic plaques in the mice as demonstrated by immunohistochemistry and appears to co-localize with macrophages. Isolated macrophages from PLTP transgenic mice do not show differences in cholesterol efflux or in cytokine production. Lipopolysaccharide activation of macrophages results in increased production of PLTP. This effect was strongly amplified in PLTP transgenic macrophages.</p></sec><sec><title>Conclusions</title><p>We conclude that PLTP expression by bone marrow derived cells results in atherogenic effects on plasma lipids, increased PLTP activity, high local PLTP protein levels in the atherosclerotic lesions and increased atherosclerotic lesion size.</p></sec></abstract><counts><page-count count="10"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Phospholipid transfer protein (PLTP) is a plasma protein with the capacity to transfer phospholipids between liposomes and lipoproteins in vitro <xref ref-type="bibr" rid="pone.0002255-Tall1">&#x0005b;1&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0002255-Albers1">&#x0005b;4&#x0005d;</xref>. In addition, PLTP can also transfer vitamin E <xref ref-type="bibr" rid="pone.0002255-Kostner1">&#x0005b;5&#x0005d;</xref> and is active as a conversion factor of high density lipoproteins (HDL) <xref ref-type="bibr" rid="pone.0002255-Tu1">&#x0005b;6&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002255-Jauhiainen1">&#x0005b;7&#x0005d;</xref>. HDL are generally considered anti-atherogenic lipoproteins by virtue of their role in cholesterol excretion (reverse cholesterol transport) <xref ref-type="bibr" rid="pone.0002255-Assmann1">&#x0005b;8&#x0005d;</xref>, although other anti-atherosclerotic properties of HDL have been described as well <xref ref-type="bibr" rid="pone.0002255-Ansell1">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002255-Barter1">&#x0005b;10&#x0005d;</xref>. Therefore, it was suggested that PLTP has a role in the development of atherosclerosis, based on its relation with HDL function <xref ref-type="bibr" rid="pone.0002255-Huuskonen1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002255-vanTol1">&#x0005b;12&#x0005d;</xref>. In vivo, phospholipids become available for PLTP-mediated transfer during lipolysis of triglyceride-rich lipoproteins, mostly chylomicrons and very low density lipoproteins (VLDL), by the enzyme lipoprotein lipase <xref ref-type="bibr" rid="pone.0002255-vanTol1">&#x0005b;12&#x0005d;</xref>. The phospholipids are transferred from triglyceride-rich lipoproteins to HDL. PLTP is able to bind to and facilitate the transfer of several types of phospholipids, including phosphatidylcholine, phosphatidylethanolamine, and phosphatidylinositol, as well as sphingomyeline <xref ref-type="bibr" rid="pone.0002255-Jiang1">&#x0005b;13&#x0005d;</xref>. In plasma, PLTP is mostly bound to HDL <xref ref-type="bibr" rid="pone.0002255-Huuskonen1">&#x0005b;11&#x0005d;</xref>.</p><p>In genetically modified mouse models the relation between the activity levels of PLTP in plasma, HDL levels, HDL subclass distribution and the development of atherosclerosis was studied in more detail. We found that a 2.5-fold increased plasma PLTP activity in transgenic mice resulted in a 30&#x00025; decrease in plasma HDL-cholesterol levels compared with wild type animals <xref ref-type="bibr" rid="pone.0002255-vanHaperen1">&#x0005b;14&#x0005d;</xref>. This represents total HDL, however. The formation of a specific subfraction of HDL, termed pre&#x003b2;-HDL, appeared to be increased in plasma from transgenic mice. Although pre&#x003b2;-HDL is a quantitatively minor HDL subfraction, it is believed to be a very efficient acceptor of cellular cholesterol and therefore an elevated production of pre&#x003b2;-HDL might result in a strong induction of reverse cholesterol transport <xref ref-type="bibr" rid="pone.0002255-Fielding1">&#x0005b;15&#x0005d;</xref>. Therefore, we suggested that PLTP increased the anti-atherogenic potential of HDL <xref ref-type="bibr" rid="pone.0002255-vanHaperen1">&#x0005b;14&#x0005d;</xref>. Subsequently Jiang and co-workers showed that PLTP deficiency was anti-atherogenic, however <xref ref-type="bibr" rid="pone.0002255-Jiang2">&#x0005b;16&#x0005d;</xref>, in spite of decreased levels of plasma HDL. The effect was attributed to a reduced production of apolipoprotein (apo)B containing lipoproteins by the liver. Indeed, we provided further evidence of an atherogenic role of PLTP in studies in a series of PLTP transgenic mouse lines with increasing levels of plasma PLTP activity, showing a PLTP-dose dependent enhancement of atherosclerosis <xref ref-type="bibr" rid="pone.0002255-VanHaperen1">&#x0005b;17&#x0005d;</xref>. We also provided in vivo evidence that PLTP is involved in the secretion of very low density lipoproteins (VLDL) <xref ref-type="bibr" rid="pone.0002255-VanHaperen1">&#x0005b;17&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002255-Lie1">&#x0005b;18&#x0005d;</xref>, but there was no PLTP-dose dependent increase of this effect in the series of PLTP transgenic mice tested <xref ref-type="bibr" rid="pone.0002255-VanHaperen1">&#x0005b;17&#x0005d;</xref>. In contrast, we observed a clear PLTP-dose dependent reduction of plasma HDL levels in parallel to the induction of atherosclerosis and therefore we concluded that elevated plasma PLTP activity in transgenic mice is atherogenic because it decreases plasma HDL. PLTP could also influence the atherogenicity of plasma lipoproteins by decreasing the vitamin E content of apoB-containing lipoproteins, resulting in increased susceptibility for oxidation <xref ref-type="bibr" rid="pone.0002255-Jiang3">&#x0005b;19&#x0005d;</xref>.</p><p>PLTP is expressed in a wide variety of cells and tissues in humans <xref ref-type="bibr" rid="pone.0002255-Day1">&#x0005b;20&#x0005d;</xref>, mice <xref ref-type="bibr" rid="pone.0002255-Albers2">&#x0005b;21&#x0005d;</xref> and human PLTP transgenic mice <xref ref-type="bibr" rid="pone.0002255-vanHaperen1">&#x0005b;14&#x0005d;</xref>. In addition, the presence of PLTP in human atherosclerotic lesions has been demonstrated <xref ref-type="bibr" rid="pone.0002255-Laffitte1">&#x0005b;22&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002255-OBrien1">&#x0005b;23&#x0005d;</xref>, which probably originates from macrophages. In order to elucidate the role of PLTP derived from bone marrow derived cells, including macrophages, to atherosclerosis, we performed in vitro studies with macrophages from PLTP transgenic mice and performed bone marrow transplantations from PLTP transgenic mice to low density lipoprotein (LDL) receptor deficient mice and subsequently studied the process of diet-induced atherosclerosis as influenced by these bone marrow transplantations.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Mice</title><p>LDLR<sup>&#x02212;/&#x02212;</sup> mice were obtained from the Jackson Laboratory (Bar Arbor, ME) and were in C57BL6/J background. Mice expressing enhanced green fluorescent protein (EGFP) under the control of the chicken beta-actin promotor and cytomegalovirus enhancer were originally generated by Okabe et al. and were in C57BL6/J background <xref ref-type="bibr" rid="pone.0002255-Okabe1">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002255-Peeters1">&#x0005b;25&#x0005d;</xref>. Human PLTP transgenic mice were generated in our laboratory as described before and are derived from the P4 line <xref ref-type="bibr" rid="pone.0002255-VanHaperen1">&#x0005b;17&#x0005d;</xref>. The transgene in these animals contains the complete human PLTP gene, including approximately 15 kb 5&#x02032; natural flanking region and 3 kb 3&#x02032; natural flanking region. The transgene is driven by its autologous human promoter. PLTP transgenic mice were crossbred to C57BL6/J background for &#x0003e;15 generations. Subsequently, homozygous PLTP transgenic mice were obtained by crossbreeding hemizygous PLTP transgenic mice. Animals were provided with food and water ad libitum. Food was either regular chow, or a high fat, high cholesterol diet containing 40&#x00025; (w/w) sucrose, 15&#x00025; (w/w) cocoa butter, and 0.25&#x00025; (w/w) cholesterol (diet W; Hope Farms, Woerden, The Netherlands). The numbers of animals used for measurements are indicated in the Figure legends. Only male mice were used. All of the procedures in this study were in accordance with national and institutional guidelines.</p></sec><sec id="s2b"><title>Bone marrow transplantation</title><p>On the day of donor cell injection, LDLR<sup>&#x02212;/&#x02212;</sup> mice of 12 weeks old were conditioned by 900 rads of &#x003b3;-irradiation from a <sup>137</sup>Cs source, which was administered in a split dose, with a 3 hours interval. Cells were injected i.v. into the tail veins. Each recipient received 5 &#x000d7; 10<sup>6</sup> bone marrow cells isolated from the femurs and tibias of the primary donors. Injected animals were provided with 0.16&#x00025; Neomycin (Sigma-Aldrich)-supplemented water. Animals were kept on a regular chow diet until 9 weeks after transplantation. During the next 9 weeks, animals were fed a high fat, high cholesterol diet.</p></sec><sec id="s2c"><title>Analysis of plasma lipids, lipoproteins, PLTP concentration and PLTP activity</title><p>Blood samples were obtained via orbital bleedings after an overnight fast at 1 week before the bone marrow transplantation, just before the start of the diet and at the end of the 9 weeks high fat, high cholesterol diet feeding. Plasma lipids (total cholesterol, phospholipids and triglycerides) were measured using commercially available kits (Wako Chemicals). Lipoprotein fractions were obtained by ultracentrifugation of plasma samples in a Beckman 42.2 Ti rotor (42000 rpm, 3 h, 12&#x000b0;C) at d&#x0200a;&#x0003d;&#x0200a;1.063 g/ml. Tubes were sliced, and two fractions were collected: non-HDL (VLDL&#x0002b;LDL), d&#x0003c;1.063 g/ml; and HDL, d&#x0003e;1.063 g/ml. PLTP activity in plasma was measured as described previously <xref ref-type="bibr" rid="pone.0002255-vanHaperen1">&#x0005b;14&#x0005d;</xref> and expressed in arbitrary units (AU). 1 AU is equivalent to the activity found in human reference plasma, which is 14 &#x000b5;mol/ml/h. PLTP concentration was measured by ELISA as described <xref ref-type="bibr" rid="pone.0002255-Lie1">&#x0005b;18&#x0005d;</xref>, using PLTP antibodies which were kindly donated by Dr. H. Hattori (BML Incorporated, Saitama, Japan). PLTP specific activity was calculated as the ratio (PLTP activity in AU)/(human PLTP concentration in mg/L).</p></sec><sec id="s2d"><title>Histological analyses and quantification of atherosclerotic lesions</title><p>Animals were anesthetized using isoflurane, and in situ fixation was performed via the left ventricle of the heart using phosphate-buffered formaldehyde (4&#x00025;, v/v). Sectioning of the aortic root, hematoxilin/eosin staining, the collection of digital images and the quantification of atherosclerotic lesions were performed as described before <xref ref-type="bibr" rid="pone.0002255-vanHaperen2">&#x0005b;26&#x0005d;</xref>.</p><p>Immunohistochemistry was performed using antibodies directed against CD68 to detect macrophages (AbD Serotec, Kidlington, UK), against CD31 to detect endothelial cells (Hycult Biotechnology BV, Uden, The Netherlands), or against vascular smooth muscle cells alpha-actin (Sigma Chemical Co., Zwijndrecht, The Netherlands) or against PLTP (kind gift of Dr. Matti Jauhiainen, Helsinki, Finland).</p></sec><sec id="s2e"><title>Cell culture studies</title><p>For the isolation of primary macrophages mice were i.p. injected with 3 mL of 40.5 g/L Bacto&#x000ae; Brewer Thioglycollate Medium (Difco International B.V., Leeuwarden, The Netherlands). After three days the animals are anesthetized using isoflurane and macrophages are isolated from the peritoneal cavity in 0.34 M sucrose. Cells were cultured in Dulbecco's Modified Eagle Medium (DMEM, Gibco, Invitrogen, Breda, The Netherlands) supplemented with 10&#x00025; (v/v) fetal bovine serum and 100 U/mL penicillin/streptomycin. Cells were seeded on 6 wells plates (3&#x000d7;10<sup>6</sup> cells/well) and kept in culture for 24 hours. Alternatively, macrophages derived from bone marrow in vitro were obtained by isolating bone marrow cells from tibias and femurs, seeding the cells on 6-wells plates (3&#x000d7;10<sup>5</sup> cells/well) and culturing them in the presence of 10 ng/ml Macrophage Colony Stimulating Factor (Biosource International, Camarillo CA, USA) <xref ref-type="bibr" rid="pone.0002255-Bouma1">&#x0005b;27&#x0005d;</xref>. The concentrations of TNF-&#x003b1;, IFN-&#x003b3;, IL-4, or IL-10 in the supernatants were measured using commercially available ELISAs (BD Biosciences Pharmingen, Alphen aan den Rijn, The Netherlands). PLTP activity was measured after 24 hours of culture in the supernatant with the same assay as used for the PLTP activity measurements in plasma. In some cases, cells were challenged by adding 100 ng/mL bacterial lipopolysaccharide (from E. coli serotype 0111:B4, Sigma, Chemical Co., Zwijndrecht, The Netherlands). In order to measure the cholesterol loading and efflux capacity <xref ref-type="bibr" rid="pone.0002255-Rothblat1">&#x0005b;28&#x0005d;</xref>, macrophages were seeded on 3 cm dishes (3&#x000d7;10<sup>6</sup> cells/dish). After 2 hours, the medium was replaced with DMEM supplemented with 1&#x00025; (v/v) fetal bovine serum, 100 U/mL penicillin/streptomycin, 30 &#x000b5;g/mL acetylated LDL (acLDL) <xref ref-type="bibr" rid="pone.0002255-Basu1">&#x0005b;29&#x0005d;</xref>, 1 &#x000b5;g/mL Acyl CoA:cholesterol acyltransferase inhibitor (gift from Sandoz AG, Basel, Switzerland) and 0.33 &#x000b5;Ci &#x0005b;<sup>3</sup>H&#x0005d;-cholesterol/mL for 22 hours. Efflux was monitored by incubating these loaded cells in DMEM containing 0.2&#x00025; (w/v) fat-free BSA (Sigma Chemical Co., #6003, Zwijndrecht, The Netherlands) and 100 &#x000b5;g/mL human HDL and sampling the medium at 1, 2, 4, and 6 hours. At the end of the efflux study, cell associated radioactive cholesterol was measured and the percentage of cholesterol efflux was calculated. Cells were lysed in 0.1 M NaOH/ 0.5&#x00025; (w/v) SDS and cellular protein was determined using the Lowry method <xref ref-type="bibr" rid="pone.0002255-Lowry1">&#x0005b;30&#x0005d;</xref>.</p></sec><sec id="s2f"><title>Statistics</title><p>All of values are expressed as mean&#x000b1;S.E. Statistical analyses are by one-way analysis of variance with Bonferroni multiple comparison tests performed with Intercooled Stata 6.0 software (Stata Corp., College Station, TX, USA).</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>PLTP production by mouse macrophages</title><p>In a first set of experiments, peritoneal macrophages were collected from three groups of mice: wild type control animals (PLTP<sup>wt/wt</sup>), hemizygous human PLTP transgenic mice (huPLTP<sup>tg/wt</sup>) and homozygous human PLTP transgenic mice (huPLTP<sup>tg/tg</sup>). Macrophages were kept in culture for 24 hours before PLTP activity was measured in the culture medium. As shown in <xref ref-type="fig" rid="pone-0002255-g001">Fig. 1</xref>, PLTP activity could be measured in the medium of cells from PLTP<sup>wt/wt</sup> mice, demonstrating that PLTP is produced and excreted by macrophages. When macrophages from huPLTP<sup>tg/wt</sup> and huPLTP<sup>tg/tg</sup> mice were tested, increased PLTP activity was found (&#x0002b;125&#x00025; and &#x0002b;233&#x00025;, respectively, both <italic>p</italic>&#x0003c;0.01). From these results we conclude that macrophages from transgenic PLTP mice have an increased production and secretion of the transgenic protein.</p><fig id="pone-0002255-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002255.g001</object-id><label>Figure 1</label><caption><title>PLTP production by mouse macrophages.</title><p>Peritoneal macrophages were collected from either C57BL/6J wild type (wt/wt), hemizygous huPLTP transgenic (tg/wt) and homozygous huPLTP transgenic (tg/tg) mice and kept in culture for 24 hours. Subsequently, PLTP activity was measured in a sample of the culture medium. PLTP activity is expressed as arbitrary units (AU; 1 AU is equivalent to 14 &#x000b5;mol/mL/h). N&#x0200a;&#x0003d;&#x0200a;cells from 6 mice per group. &#x0002a;&#x0002a; <italic>p</italic>&#x0003c;0.005 versus wt/wt; &#x00024; <italic>p</italic>&#x0003c;0.01 versus tg/wt.</p></caption><graphic xlink:href="pone.0002255.g001"/></fig></sec><sec id="s3b"><title>Effects of bone marrow transplantation on plasma PLTP activity</title><p>In order to study the contribution of PLTP expression by bone marrow derived cells on plasma PLTP activity, we performed bone marrow transplantation experiments from PLTP<sup>wt/wt</sup>, huPLTP<sup>tg/wt</sup> and huPLTP<sup>tg/tg</sup> mice to lethally irradiated LDL-receptor deficient (LDLR<sup>&#x02212;/&#x02212;</sup>) mice. Following the transplantation, animals were allowed to recover for 9 weeks. Subsequently, animals were fed a high fat, high cholesterol diet for another 9 weeks period. Blood samples were collected one week before irradiation, just before starting the diet and at the end of the 9 weeks diet period (time points -10 weeks, 0 weeks and 9 weeks, relative to the start of the diet, respectively). In addition to the transplanted animals, groups of LDLR<sup>&#x02212;/&#x02212;</sup> mice and LDLR<sup>&#x02212;/&#x02212;</sup>/huPLTP<sup>tg/wt</sup> mice were subjected to the same series of experiments, except the irradiation and bone marrow transplantation. Blood samples were collected at 0 weeks and 9 weeks. Animals were age matched to the mice in the transplantation groups.</p><p>As shown in <xref ref-type="fig" rid="pone-0002255-g002">Fig. 2A</xref> (left panel), plasma PLTP activity in LDLR<sup>&#x02212;/&#x02212;</sup>/huPLTP<sup>tg/wt</sup> mice were approximately 3-fold higher than in LDLR<sup>&#x02212;/&#x02212;</sup> mice when fed a chow diet (0 weeks). After feeding the animals a high fat, high cholesterol diet for 9 weeks, plasma PLTP activity in both LDLR<sup>&#x02212;/&#x02212;</sup> and LDLR<sup>&#x02212;/&#x02212;</sup>/huPLTP<sup>tg/wt</sup> mice was increased by about 2-fold when compared to chow fed animals of the same genotype.</p><fig id="pone-0002255-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002255.g002</object-id><label>Figure 2</label><caption><title>Plasma PLTP levels.</title><p>A. PLTP activity was measured in plasma samples and expressed in arbitrary units as described in the legend of <xref ref-type="fig" rid="pone-0002255-g001">Fig. 1</xref>. Left panel: plasma samples were collected from non-transplanted LDLR<sup>&#x02212;/&#x02212;</sup> and LDLR<sup>&#x02212;/&#x02212;</sup>/huPLTP<sup>tg/wt</sup> mice just before the start of the high fat, high cholesterol diet (0 weeks, white bars) and after 9 weeks of the diet (9 weeks, black bars). &#x0002a;&#x0002a;&#x0002a; <italic>p</italic>&#x0003c;0.001 versus 0 weeks (same genotype), ### <italic>p</italic>&#x0003c;0.001 versus LDLR<sup>&#x02212;/&#x02212;</sup> mice (on the same diet). Right panel: plasma samples were collected from PLTP<sup>wt/wt</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup>, huPLTP<sup>tg/wt</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup>, and huPLTP<sup>tg/tg</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> recipient mice at 1 week before the start of the transplantation procedure (i.e. at 10 weeks before the start of the diet: &#x02212;10 weeks, grey bars), just before the start of the diet (0 weeks, white bars) and after 9 weeks of diet (9 weeks, black bars). &#x0002a;&#x0002a;&#x0002a; <italic>p</italic>&#x0003c;0.001 versus &#x02212;10 weeks (same genotype); ### <italic>p</italic>&#x0003c;0.001 versus PLTP<sup>wt/wt</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice (on the same diet); &#x000b6;&#x000b6;&#x000b6; <italic>p</italic>&#x0003c;0.001 versus 0 weeks (same genotype). B. Mass of human PLTP in plasma from mice was measured by ELISA as described in Methods in the Supplemental Data. C. Specific Activities of PLTP were calculated using the ratio between the activity in AU and the mass in mg/L. &#x000b6;&#x000b6;&#x000b6; <italic>p</italic>&#x0003c;0.001 versus 0 weeks (same genotype); &#x00024;&#x00024;&#x00024; <italic>p</italic>&#x0003c;0.001 versus PLTP<sup>tg/wt</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice (on the same diet). N&#x0200a;&#x0003d;&#x0200a;11&#x02013;15 mice per group.</p></caption><graphic xlink:href="pone.0002255.g002"/></fig><p><xref ref-type="fig" rid="pone-0002255-g002">Fig. 2A</xref> (right panel) also shows the plasma PLTP activity in transplanted animals. The transplantation procedure itself resulted in a significant increase in PLTP activity, ranging from 29&#x00025; in the PLTP<sup>wt/wt</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice to 88&#x00025; in the huPLTP<sup>tg/tg</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice (all <italic>p&#x0003c;</italic>0.001). After feeding the animals a high fat, high cholesterol diet, a further increase in plasma PLTP activity was observed ranging from 82&#x00025; in the PLTP<sup>wt/wt</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice to 113&#x00025; in the huPLTP<sup>tg/tg</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice (all <italic>p&#x0003c;</italic>0.001). Under both dietary conditions, plasma PLTP activity did not differ between huPLTP<sup>tg/wt</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> and huPLTP<sup>tg/tg</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice.</p><p><xref ref-type="fig" rid="pone-0002255-g002">Fig. 2B</xref> shows the concentration of human PLTP in plasma from transplanted animals. As there is no ELISA available for mouse PLTP, mass of plasma PLTP could only be measured in the huPLTP<sup>tg/wt</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> and huPLTP<sup>tg/tg</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice. The PLTP concentration appeared to be approximately twice as much in the latter animals. The high fat, high cholesterol diet resulted in a two-fold increase in PLTP mass. The specific activity of plasma PLTP was not affected by the diet (<xref ref-type="fig" rid="pone-0002255-g002">Fig. 2C</xref>). Interestingly however, the specific activity in the huPLTP<sup>tg/tg</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice was significantly lower than in the huPLTP<sup>tg/wt</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice, implying that part of the huPLTP in the huPLTP<sup>tg/tg</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice is in the inactive form.</p></sec><sec id="s3c"><title>Effects of bone marrow transplantation on plasma lipids and lipoproteins</title><p>When fed a regular chow diet, plasma cholesterol levels were slightly decreased in LDLR<sup>&#x02212;/&#x02212;</sup>/huPLTP<sup>tg/wt</sup> mice when compared to LDLR<sup>&#x02212;/&#x02212;</sup> mice (<xref ref-type="fig" rid="pone-0002255-g003">Fig. 3A, left panel</xref>). However, this difference was absent after feeding the animals a high fat, high cholesterol diet for 9 weeks. In the transplanted animals, no major differences in plasma cholesterol concentration were observed between the various groups on chow diet (<xref ref-type="fig" rid="pone-0002255-g003">Fig. 3A, right panel</xref>). However, after feeding the animals a high fat, high cholesterol diet for 9 weeks an increase in cholesterol concentration was observed in PLTP<sup>wt/wt</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup>, huPLTP<sup>tg/wt</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup>, and huPLTP<sup>tg/tg</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice. Effects on plasma phospholipids and triglycerides largely mirrored those on plasma cholesterol (<xref ref-type="fig" rid="pone-0002255-g003">Fig. 3B,C</xref>). In order to further investigate these differences, HDL and non-HDL was separated in plasma samples of the animals after 9 weeks on a high fat, high cholesterol diet. The mice transplanted with huPLTP transgenic bone marrow cells showed an increase in non-HDL cholesterol (<xref ref-type="fig" rid="pone-0002255-g004">Fig. 4A</xref>) and a decrease in HDL-cholesterol (<xref ref-type="fig" rid="pone-0002255-g004">Fig. 4B</xref>) when compared with the mice transplanted with wild type bone marrow cells.</p><fig id="pone-0002255-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002255.g003</object-id><label>Figure 3</label><caption><title>Plasma lipid levels.</title><p>Plasma levels of cholesterol (A), phospholipids (B) and triglycerides (C) were measured as described in <xref ref-type="sec" rid="s2">Methods</xref>. Left panels: Plasma samples were collected from non-transplanted LDLR<sup>&#x02212;/&#x02212;</sup> and LDLR<sup>&#x02212;/&#x02212;</sup>/huPLTP<sup>tg/wt</sup> mice just before the start of the high fat, high cholesterol diet (0 weeks, white bars) and after 9 weeks of the diet (9 weeks, black bars). &#x0002a;&#x0002a;&#x0002a; <italic>p</italic>&#x0003c;0.001 versus 0 weeks (same genotype), ### <italic>p</italic>&#x0003c;0.001 versus LDLR<sup>&#x02212;/&#x02212;</sup> mice (on the same diet). Right panels: plasma samples were collected from PLTP<sup>wt/wt</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup>, huPLTP<sup>tg/wt</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup>, and huPLTP<sup>tg/tg</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> recipient mice at 1 week before the start of the transplantation procedure (i.e. at 10 weeks before the start of the diet: &#x02212;10 weeks, grey bars), just before the start of the diet (0 weeks, white bars) and after 9 weeks of diet (9 weeks, black bars). N&#x0200a;&#x0003d;&#x0200a;11&#x02013;15 mice per group. &#x0002a; <italic>p</italic>&#x0003c;0.05, &#x0002a;&#x0002a;&#x0002a; <italic>p</italic>&#x0003c;0.001 versus &#x02212;10 weeks (same genotype); ### <italic>p</italic>&#x0003c;0.001 versus PLTP<sup>wt/wt</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice (on the same diet).</p></caption><graphic xlink:href="pone.0002255.g003"/></fig><fig id="pone-0002255-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002255.g004</object-id><label>Figure 4</label><caption><title>Plasma levels of non-HDL cholesterol and HDL cholesterol.</title><p>Plasma was collected from PLTP<sup>wt/wt</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup>, huPLTP<sup>tg/wt</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup>, and huPLTP<sup>tg/tg</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> recipient mice at the end of the high fat, high cholesterol diet period (i.e., at time of sacrifice) and separated into two fractions: d&#x0003c;1.063 g/L (non-HDL) and d&#x0003e;1.063 g/L (HDL) by ultracentrifugation. In both fractions, the cholesterol concentration was measured. A: non-HDL cholesterol; B: HDL-cholesterol. N&#x0200a;&#x0003d;&#x0200a;11&#x02013;15 mice per group. &#x0002a;&#x0002a; <italic>p</italic>&#x0003c;0.01, &#x0002a;&#x0002a;&#x0002a; <italic>p</italic>&#x0003c;0.001 versus PLTP<sup>wt/wt</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice; &#x00024;&#x00024;&#x00024; <italic>p</italic>&#x0003c;0.001 versus huPLTP<sup>tg/wt</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice.</p></caption><graphic xlink:href="pone.0002255.g004"/></fig></sec><sec id="s3d"><title>Effects of bone marrow transplantation on atherosclerosis</title><p>After feeding the animals a high fat, high cholesterol diet for 9 weeks, atherosclerosis was quantified by measuring the area of atherosclerotic lesions in the aortic root. In agreement with previous studies from our laboratory <xref ref-type="bibr" rid="pone.0002255-VanHaperen1">&#x0005b;17&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002255-Lie2">&#x0005b;31&#x0005d;</xref>, we found that elevated levels of PLTP result in a strong increase (312&#x00025;) in diet-induced atherosclerosis in non-transplanted mice (<xref ref-type="fig" rid="pone-0002255-g005">Fig. 5A, left panel</xref>; <italic>p&#x0003c;</italic>0.001). In transplanted mice, a clear increase in atherosclerotic lesion area was observed (<xref ref-type="fig" rid="pone-0002255-g005">Fig. 5A, right panel</xref>; all differences <italic>p&#x0003c;</italic>0.001). Compared to PLTP<sup>wt/wt</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice, huPLTP<sup>tg/wt</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice have an increase of 128&#x00025; in atherosclerotic lesion area, while huPLTP<sup>tg/tg</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice have an increase of 348&#x00025; in atherosclerotic lesion area.</p><fig id="pone-0002255-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002255.g005</object-id><label>Figure 5</label><caption><title>Atherosclerosis in non-transplanted and transplanted mice.</title><p>A. Plaque area was measured in sections from the aortic root (see <xref ref-type="sec" rid="s2">Methods</xref>). Left panel: Plaque area in non-transplanted LDLR<sup>&#x02212;/&#x02212;</sup> and LDLR<sup>&#x02212;/&#x02212;</sup>/huPLTP<sup>tg/wt</sup> mice. &#x0002a;&#x0002a;&#x0002a; <italic>p</italic>&#x0003c;0.001 versus LDLR<sup>&#x02212;/&#x02212;</sup> mice. Right panel: Plaque area in PLTPwt/wt&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup>, huPLTP<sup>tg/wt</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup>, and huPLTP<sup>tg/tg</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> recipient mice. N&#x0200a;&#x0003d;&#x0200a;11&#x02013;15 mice per group. &#x0002a;&#x0002a;&#x0002a; <italic>p</italic>&#x0003c;0.001 versus PLTP<sup>wt/wt</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice; &#x00024;&#x00024;&#x00024; &#x0002a;&#x0002a;&#x0002a; <italic>p</italic>&#x0003c;0.001 versus huPLTP<sup>tg/wt</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice. B, C. Immunohistochemistry of atherosclerotic lesions from non-transplanted LDLR<sup>&#x02212;/&#x02212;</sup>/huPLTP<sup>tg/wt</sup> mice (B) and from transplanted huPLTP<sup>tg/tg</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice (C), stained for macrophages (M&#x003a6;) with anti-CD68 and for PLTP and counterstained with Nuclear-fast red (serial sections). The right panels are magnifications of the boxed parts in the left panels. Original magnifications: 100x (B) and 250x (C).</p></caption><graphic xlink:href="pone.0002255.g005"/></fig><p>The presence of PLTP expressing macrophages in the aortic lesions was confirmed by immunohistochemistry. As illustrated in <xref ref-type="fig" rid="pone-0002255-g005">Fig. 5</xref>, the plaques from both non-transplanted LDLR<sup>&#x02212;/&#x02212;</sup>/huPLTP<sup>tg/wt</sup> mice (<xref ref-type="fig" rid="pone-0002255-g005">Fig. 5B</xref>) as those from recipient huPLTP<sup>tg/tg</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice (<xref ref-type="fig" rid="pone-0002255-g005">Fig. 5C</xref>) contain considerable amounts of macrophages while PLTP is co-localized in similar areas of the lesions.</p><p>In order to be more conclusive on the nature of the bone marrow derived cells, we performed an additional set of experiments using actin-EGFP mice as donors and LDLR<sup>&#x02212;/&#x02212;</sup> mice as acceptors, using exactly the same experimental procedure to obtain diet-induced atherosclerosis. Sections from the aortic root were inspected using confocal microscopy after immunohistochemistry with antibodies directed against CD68 as a marker for macrophages or VSMC &#x003b1;-actin as a marker for VSMCs. DAPI staining was used to visualize nuclei. Bone marrow derived donor cells, identified by the GFP signal, are clearly present in the subendothelial space of the early lesions and co-localize to a great extent with CD68 (<xref ref-type="fig" rid="pone-0002255-g006">Fig. 6A,B</xref>). In the advanced lesions, the cell-rich regions show significant co-localization of the GFP and CD68 signals, while the necrotic core stills allows detection of CD68, but GFP is no longer expressed (<xref ref-type="fig" rid="pone-0002255-g006">Fig. 6C,D</xref>). In early lesions, VSMCs are almost exclusively located in the media (<xref ref-type="fig" rid="pone-0002255-g006">Fig. 6B</xref>). In advanced lesions, VSMCs can be detected in the fibrous cap (<xref ref-type="fig" rid="pone-0002255-g006">Fig. 6D</xref>), but they do not co-localize with GFP, demonstrating that also the VSMCs in the lesions are not donor-derived. As shown in <xref ref-type="fig" rid="pone-0002255-g006">Fig. 6A&#x02013;D</xref>, isolated nuclei can be detected of endothelial cells covering the lesions without GFP signal, demonstrating that these cells are not donor-derived. Positive staining for endothelial cells was performed by using an antibody directed against CD31 (<xref ref-type="fig" rid="pone-0002255-g006">Fig. 6E,F</xref>). The endothelial lining in early (<xref ref-type="fig" rid="pone-0002255-g006">Fig. 6E</xref>) and in advanced (<xref ref-type="fig" rid="pone-0002255-g006">Fig. 6F</xref>) lesions is continuous and does not express GFP, implying that the endothelial cells are not donor derived.</p><fig id="pone-0002255-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002255.g006</object-id><label>Figure 6</label><caption><title>Transplantations with &#x003b2;-actin GFP mice&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice.</title><p>A&#x02013;D: Early lesions (A,B) and advanced lesions (C,D) with donor cells expressing GFP (green), CD 68 (marker for macrophages) in red (A,C) and &#x003b1;-actin (marker for VSMCs) in red (B,D) and nuclei stained with DAPI (blue). Endothelial cells covering the lesions do not express GFP (nuclei indicated with arrows). Co-localization of GFP and CD68 results in an orange color (arrowheads). The necrotic core in the advanced lesion (located centrally in C and D) is diffusely positive for CD68 but does not show any GFP signal. The media is marked with a double arrow (&#x02194;). E,F: Early lesion (E) and advanced lesion (F) with donor cells expressing GFP (green), and CD 31 (marker for endothelial cells) in red (arrows). Representative pictures from N&#x0200a;&#x0003d;&#x0200a;6 animals are shown. Original magnifications: 200X.</p></caption><graphic xlink:href="pone.0002255.g006"/></fig></sec><sec id="s3e"><title>Characterization of PLTP expressing macrophages</title><p>In order to investigate the mechanism by which mice transplanted with bone marrow cells expressing elevated levels of PLTP develop more atherosclerosis, we performed a series of in vitro studies using primary macrophages from PLTP<sup>wt/wt</sup>, huPLTP<sup>tg/wt</sup>, and huPLTP<sup>tg/tg</sup> mice, respectively.</p><p>First we examined whether PLTP expression in macrophages affects their capacity to perform cellular cholesterol efflux. To this end, macrophages were loaded with radiolabeled cholesterol using acLDL and efflux to the medium was studied during six hours using human HDL as an acceptor. There was no difference in cholesterol loading between macrophages from PLTP<sup>wt/wt</sup> and huPLTP<sup>tg/tg</sup> mice (42.87&#x0002b;/&#x02212;8.25 versus 44.26&#x0002b;/&#x02212;8.67&#x00025; &#x0005b;<sup>3</sup>H&#x0005d;cholesterol/mg cell protein). No difference in efflux to HDL was observed (<xref ref-type="fig" rid="pone-0002255-g007">Fig. 7A</xref>). Consequently, the amount of radioactive cholesterol that remained cell-associated at the end of the efflux period was also similar (not shown).</p><fig id="pone-0002255-g007" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0002255.g007</object-id><label>Figure 7</label><caption><title>Characteristics of mouse macrophages.</title><p>A. Cholesterol efflux from cultured peritoneal macrophages. Cells were loaded with radioactive cholesterol as described in <xref ref-type="sec" rid="s2">Methods</xref>. Subsequently, culture medium with human HDL as an acceptor was added. Left panel: Radioactivity was measured in aliquots from the cultured medium taken at 0, 1, 2, 4, and 6 hours. Circles: macrophages from C57BL/6J mice, squares: macrophages from huPLTP<sup>tg/tg</sup> mice. Differences were not statistically significant. B. PLTP activity measured in the medium of macrophages cultured for 24 hours in the absence (white bars) or presence (black bars) of 100 ng/mL LPS. Cells from 6 mice were used per group. C. PLTP activity measured in plasma samples from mice treated with thioglycolate. N&#x0200a;&#x0003d;&#x0200a;6 mice per group. &#x0002a;&#x0002a; <italic>p</italic>&#x0003c;0.005, &#x0002a;&#x0002a;&#x0002a; <italic>p</italic>&#x0003c;0.001 versus cells without LPS or thioglycolate (same genotype), ## <italic>p</italic>&#x0003c;0.005, ### <italic>p</italic>&#x0003c;0.001 versus PLPT<sup>wt/wt</sup> (same culture medium, with or without LPS or thioglycolate).</p></caption><graphic xlink:href="pone.0002255.g007"/></fig><p>Possible differences between the inflammatory status of the macrophages were studied by comparing the level of the cytokines, TNF-&#x003b1;, IFN-&#x003b3;, IL-4, and IL-10, by ELISA. No differences were found in medium from macrophages obtained from PLTP<sup>wt/wt</sup>, huPLTP<sup>tg/wt</sup>, and huPLTP<sup>tg/tg</sup> mice before or after stimulation with LPS (results not shown). These results indicate that there is no difference in cytokine production by macrophages from these mice.</p><p>Subsequently, we studied whether activated macrophages have different PLTP activity. Therefore, we challenged the macrophages with bacterial lipopolysaccharide (LPS), and measured PLTP activity in the medium from the stimulated macrophages. As shown in <xref ref-type="fig" rid="pone-0002255-g007">Fig. 7B</xref>, stimulation of macrophages from PLTP<sup>wt/wt</sup> mice with LPS resulted in approximately 70&#x00025; increase in PLTP activity. Unstimulated macrophages from huPLTP<sup>tg/wt</sup> or huPLTP<sup>tg/tg</sup> mice secreted approximately 2.5 to 4 fold more PLTP in the culture medium than macrophages from PLTP<sup>wt/wt</sup> mice. LPS stimulation resulted in a further 7.5 fold increase of PLTP activity in the culture medium from macrophages from huPLTP<sup>tg/wt</sup> or huPLTP<sup>tg/tg</sup> mice. In order to investigate whether this in vitro effect would be reflected by similar effects in vivo, we measured plasma PLTP activity levels in both PLTP<sup>wt/wt</sup> and huPLTP<sup>tg/tg</sup> mice that were treated with thioglycolate. In both cases, this treatment resulted in a statistically significant (P&#x0003c;0.002) increase in plasma PLTP activity (<xref ref-type="fig" rid="pone-0002255-g007">Fig. 7C</xref>).</p><p>Finally, we cultured macrophages from bone marrow in order to consolidate these findings. Comparing macrophages from PLTP<sup>wt/wt</sup> and huPLTP<sup>tg/tg</sup> mice, we found much more PLTP activity in the medium of the huPLTP<sup>tg/tg</sup> cells. PLTP activity could be significantly increased in cells from both PLTP<sup>wt/wt</sup> and huPLTP<sup>tg/tg</sup> mice after treatment with LPS (not shown).</p></sec></sec><sec id="s4"><title>Discussion</title><p>The main findings of this study are: (1) Mouse macrophages express and secrete PLTP while mouse macrophages from human PLTP transgenic mice express and secrete increased levels of PLTP; (2) Bone marrow transplantations using PLTP transgenic mice as donors induce elevated plasma PLTP activity levels in the acceptor mice; (3) PLTP overexpression results in decreased plasma levels of HDL cholesterol and in increased plasma levels of non-HDL cholesterol; (4) Transplantation with PLTP expressing bone marrow cells results in increased (2&#x02013;4.5 fold) atherosclerosis with abundant intra-plaque presence of PLTP.</p><p>The potential relevance of PLTP production by macrophages is emphasized by three independent studies, showing that PLTP protein is present in human atherosclerotic lesions <xref ref-type="bibr" rid="pone.0002255-Laffitte1">&#x0005b;22&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002255-OBrien1">&#x0005b;23&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002255-Desrumaux1">&#x0005b;32&#x0005d;</xref>. Although intriguing, the presence of PLTP in atherosclerotic lesions per se does not prove a direct involvement in the process of atherosclerosis and therefore the significance of these findings is unclear. In humans, the causal relation between PLTP and atherosclerosis is still uncertain <xref ref-type="bibr" rid="pone.0002255-Stein1">&#x0005b;33&#x0005d;</xref>. Plasma PLTP activity is elevated in patients suffering from diabetes mellitus type 1 <xref ref-type="bibr" rid="pone.0002255-Colhoun1">&#x0005b;34&#x0005d;</xref> and type 2 <xref ref-type="bibr" rid="pone.0002255-Riemens1">&#x0005b;35&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002255-Desrumaux2">&#x0005b;36&#x0005d;</xref>. In addition, increased PLTP is found in obese individuals <xref ref-type="bibr" rid="pone.0002255-Dullaart1">&#x0005b;37&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0002255-Murdoch1">&#x0005b;40&#x0005d;</xref> while it is decreased with weight loss <xref ref-type="bibr" rid="pone.0002255-Murdoch2">&#x0005b;41&#x0005d;</xref>. The elevated plasma PLTP activity in patients with type 2 diabetes mellitus is positively correlated with the carotid intima-media thickness <xref ref-type="bibr" rid="pone.0002255-deVries1">&#x0005b;42&#x0005d;</xref>.</p><p>In order to find out what the contribution of PLTP expressing macrophages to diet induced atherosclerosis would be, we performed bone marrow transplantation experiments.</p><p>9 weeks after bone marrow transplantation, a moderate increase in plasma PLTP activity was found in the animals transplanted with PLTP<sup>wt/wt</sup> cells. In the animals transplanted with PLTP transgenic cells, a further increase was observed. Feeding the animals a high fat, high cholesterol diet for 9 weeks, resulted in a striking increase in plasma PLTP activity. It has been demonstrated that cholesterol loading of macrophages induces a strong (2&#x02013;3 fold) induction of PLTP mRNA, PLTP protein secretion and an increased PLTP activity in the medium conditioned by these cells <xref ref-type="bibr" rid="pone.0002255-OBrien1">&#x0005b;23&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002255-Desrumaux1">&#x0005b;32&#x0005d;</xref>. Our results show that in animals fed a high fat, high cholesterol diet, plasma from huPLTP<sup>tg/wt</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> and huPLTP<sup>tg/tg</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice have a 66&#x02013;75&#x00025; increase in PLTP activity when compared to plasma from PLTP<sup>wt/wt</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice. Thus we conclude that a considerable amount of macrophage PLTP is excreted into the blood.</p><p>An increase in plasma PLTP activity affects plasma lipids. Plasma cholesterol is not affected by the moderate increase in PLTP activity caused by the bone marrow transplantation procedure itself. After 9 weeks of high fat, high cholesterol diet plasma cholesterol is elevated, as expected, but a further increase is observed in the huPLTP<sup>tg/wt</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> and huPLTP<sup>tg/tg</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice. So, PLTP expression by bone marrow derived cells affects not only plasma PLTP activity levels, but also plasma lipids.</p><p>Because PLTP activity can be directly measured in plasma, our experiments clearly show that PLTP is excreted by bone marrow derived cells into the plasma compartment. Probably this is the cause of the observed decrease in plasma HDL cholesterol, which is in agreement with previous results from our laboratory <xref ref-type="bibr" rid="pone.0002255-vanHaperen1">&#x0005b;14&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002255-VanHaperen1">&#x0005b;17&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002255-Lie2">&#x0005b;31&#x0005d;</xref> and others <xref ref-type="bibr" rid="pone.0002255-Foger1">&#x0005b;43&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002255-Ehnholm1">&#x0005b;44&#x0005d;</xref>, and which is probably caused by an enhanced catabolism of HDL <xref ref-type="bibr" rid="pone.0002255-Foger1">&#x0005b;43&#x0005d;</xref>. Most likely, this effect will contribute to the observed enhanced atherosclerosis in mice transplanted with huPLTP transgenic bone marrow. In addition however, there might be a local effect of PLTP produced by macrophages in the vascular wall. Although PLTP overexpressing macrophages do not show any difference in cholesterol efflux capacity or cytokine production, a very strong induction of PLTP production is observed in macrophages treated with LPS. So, activated macrophages present in the inflammatory environment of atherosclerotic plaques probably excrete large amounts of PLTP. This is confirmed by immunohistochemistry data in the present study. The high local PLTP production might result in a further increase of the inflammatory status of the lesions. Additional support for this idea is provided by studies showing that PLTP deficiency is associated with anti-inflammatory effects <xref ref-type="bibr" rid="pone.0002255-Yan1">&#x0005b;45&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002255-Schlitt1">&#x0005b;46&#x0005d;</xref>, and by a study in which an association was found between PLTP activity and inflammatory markers in patients with cardiovascular disease <xref ref-type="bibr" rid="pone.0002255-Cheung2">&#x0005b;47&#x0005d;</xref>. Alternatively, extracellular PLTP might act as a trap for HDL. PLTP is able to bind to the extracellular matrix proteoglycan biglycan <xref ref-type="bibr" rid="pone.0002255-OBrien1">&#x0005b;23&#x0005d;</xref> and thus act as a bridging molecule to bind HDL. In vitro studies showed that this action is independent of PLTP's phospholipid transfer activity. By trapping HDL in the atherosclerotic lesion, PLTP could interfere with the reverse cholesterol transport activity of HDL and thus enhance lipid accumulation, or actually, inhibit lipid removal, and hence stimulate the development of the plaque. It is uncertain whether this HDL retention may contribute to the decreased plasma levels of HDL observed in mice transplanted with huPLTP transgenic bone marrow.</p><p>While macrophage expression of PLTP has both systemic and local effects, both of which might be atherogenic, the steep increase in atherosclerotic lesion size of almost 2-fold between huPLTP<sup>tg/wt</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> and huPLTP<sup>tg/tg</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice is not completely reflected by the differences in the systemic effects, as these mice have similar plasma PLTP activities. This suggests that local effects of PLTP expression might indeed play an important role. In addition, the huPLTP<sup>tg/tg</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice show a reduced specific activity of PLTP. This could indicate that the huPLTP<sup>tg/tg</sup>&#x02192;LDLR<sup>&#x02212;/&#x02212;</sup> mice have relatively more inactive PLTP <xref ref-type="bibr" rid="pone.0002255-Karkkainen1">&#x0005b;48&#x0005d;</xref>, which may not have phospholipids transfer activity, but which might still have some of the other effects described above. Also, PLTP secreted by the huPLTP<sup>tg/tg</sup> bone marrow derived cells in the transplanted animals finds itself in a plasma environment with very little HDL. As active PLTP is normally bound to HDL, this situation could destabilize PLTP resulting in partial PLTP inactivation and in a decrease in PLTP specific activity.</p><p>It should be noted that bone marrow derived cells include cells other than macrophages, like endothelial cells and VSMCs. Therefore, we performed a set of control experiments with &#x003b2;-actin GFP donor mice. It became clear that using our experimental conditions, the contribution from bone marrow derived endothelial cells or VSMCs to the atherosclerotic lesion is undetectable, while there is a significant number of bone marrow derived macrophages in the lesions.</p><p>Recently, the susceptibility to diet-induced atherosclerosis was studied in mice after bone marrow transplantations with bone marrow cells from wild type and PLTP deficient mice. Strikingly different results were reported by two independent research groups, leading to opposite conclusions <xref ref-type="bibr" rid="pone.0002255-Valenta1">&#x0005b;49&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0002255-Vikstedt1">&#x0005b;50&#x0005d;</xref>. While Valenta et al <xref ref-type="bibr" rid="pone.0002255-Valenta1">&#x0005b;49&#x0005d;</xref> propose an athero-protective role for macrophage derived PLTP, Vikstedt et al <xref ref-type="bibr" rid="pone.0002255-Vikstedt1">&#x0005b;50&#x0005d;</xref> show evidence for an atherogenic function of macrophage derived PLTP. Both groups used LDLR<sup>&#x02212;/&#x02212;</sup> mice as acceptors, and either wild type or PLTP<sup>&#x02212;/&#x02212;</sup> mice as donors. All mice had the same genetic background (C57BL/6J), and the same strain of PLTP deficient mice were used. When comparing mice transplanted with PLTP<sup>&#x02212;/&#x02212;</sup> bone marrow with mice transplanted with wild type bone marrow, Valenta et al found an increase in atherosclerotic lesion area in of 30&#x00025; (measured in the aortic valves) or 28&#x00025; (measured in the entire aorta), while Vikstedt et al found a decrease of 29&#x00025; (measured in the aortic valves). In both studies, plasma PLTP activity is lower in mice transplanted with PLTP<sup>&#x02212;/&#x02212;</sup> bone marrow than in mice transplanted with wild type bone marrow when fed a chow diet, and the difference becomes larger in mice fed an atherogenic diet. In the study by Vikstedt et al this leads to a significant decrease in plasma cholesterol levels and an increase in HDL, which may explain the decreased atherosclerosis found in mice transplanted with PLTP<sup>&#x02212;/&#x02212;</sup> bone marrow. In the study by Valenta et al there is increased atherosclerosis while plasma cholesterol levels are hardly changed. Thus, in the latter study postulated that plasma PLTP is atherogenic, while PLTP which is locally active in the vascular wall may have anti-atherogenic potential, possibly by local stimulation of macrophage cholesterol efflux.</p><p>Vikstedt et al have summarized the major differences in experimental set-up: 1) Vikstedt et al used female mice as acceptors while Valenta et al used male mice; 2) Vikstedt et al fed the mice an atherogenic diet with 0.25&#x00025; cholesterol for 9 weeks while the diet used by Valenta et al contained 1.25&#x00025; cholesterol and was fed for 16 weeks; 3) Vikstedt et al allowed the mice to recover from the bone marrow transplantation procedure for 8 weeks before the atherogenic diet was supplied while Valenta et al applied a recovery time of only 4 weeks. Vikstedt et al do not indicate if any of these differences could be the deciding factor to explain the different outcomes of their studies.</p><p>Very recently, Valenta et al confirmed their previous findings in a study in which they used LDLR<sup>&#x02212;/&#x02212;</sup>/PLTP<sup>&#x02212;/&#x02212;</sup> mice as acceptors <xref ref-type="bibr" rid="pone.0002255-Valenta2">&#x0005b;51&#x0005d;</xref>. Here, they applied the same experimental set-up as in their earlier work. In the discussion of this recent paper, the differences with the experimental set-up followed by Vikstedt et al are listed, but there are no conclusions about what might really cause the different outcomes.</p><p>We believe that the difference in gender between the recipients in the studies using PLTP deficient mice is not a likely explanation for the conflicting results. Although it is well-known that the susceptibility of female and male mice to atherosclerosis is different, the reason for this phenomenon is unknown, and, to the best of our knowledge, there are no reports where opposite outcomes of an intervention with respect to atherosclerosis susceptibility between males and females have been described. In fact, we have shown in a previous study that in animals with elevated PLTP activity, both males and females have more atherosclerosis <xref ref-type="bibr" rid="pone.0002255-Lie3">&#x0005b;52&#x0005d;</xref>.</p><p>The difference in diet-regime may be an essential factor. The diet used by Valenta et al contains five times as much cholesterol as the diet used by Vikstedt et al and was applied much longer. Therefore, this is a significantly more aggressive way of induction of atherosclerosis. It is conceivable that this has affected the outcome of the study.</p><p>The difference in recovery time may be an essential factor as well. Vikstedt et al allowed the animals to recover for eight weeks, compared to four weeks in the study of Valenta et al. Four weeks is really a very short time, in which the hematopoietic system has not yet been stably reconstituted. It is conceivable, that PLTP deficiency affects the repopulation of monocytes/macrophages. Therefore, the development of atherosclerotic lesions may be affected by differences in recovery time. Also, the reconstitution of resident macrophages in lung and liver, both important sites of PLTP expression, may not yet be stable after only four weeks of recovery <xref ref-type="bibr" rid="pone.0002255-Jordan1">&#x0005b;53&#x0005d;</xref>.</p><p>We studied the effects of elevated PLTP expression using transgenic mouse models that have been developed in our own laboratory. The interpretation of our results is independent from the conflicting results that have been reported using PLTP<sup>&#x02212;/&#x02212;</sup> mice. Our experimental set-up is comparable to the one used by Vikstedt et al, as we also fed the mice a diet containing 0.25&#x00025; cholesterol for 9 weeks, and we used an even slightly longer recovery period (9 weeks). Their results are in line with our findings, as we report an increase of atherosclerosis in mice transplanted with PLTP overexpressing bone marrow, while they found decreased atherosclerosis in mice transplanted with PLTP<sup>&#x02212;/&#x02212;</sup> bone marrow cells.</p><p>In conclusion, we showed that elevated macrophage expression of PLTP results in increased atherosclerosis. This is probably directly related to the effects on plasma lipoproteins caused by PLTP expression by bone marrow derived cells. In addition, local effects in the atherosclerotic lesion could contribute to this process. These results indicate that the presence of PLTP in human atherosclerotic lesions probably contributes to the pathologic process and that inhibition of PLTP accumulation in atherosclerotic lesions may be a valuable target for therapy.</p></sec></body><back><ack><p>We would like to thank Dr. Pieter Leenen for advice on immunological methods and Hans Diepstraten for excellent technical assistance with animal experiments.</p></ack><ref-list><title>References</title><ref id="pone.0002255-Tall1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tall</surname><given-names>AR</given-names></name></person-group><year>1980</year><article-title>Studies on the transfer of phosphatidylcholine from unilamellar vesicles into plasma high density lipoproteins in the rat.</article-title><source>J Lipid Res</source><volume>21</volume><fpage>354</fpage><lpage>363</lpage><pub-id pub-id-type="pmid">7381329</pub-id></citation></ref><ref id="pone.0002255-Damen1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Damen</surname><given-names>J</given-names></name><name><surname>Regts</surname><given-names>J</given-names></name><name><surname>Scherphof</surname><given-names>G</given-names></name></person-group><year>1982</year><article-title>Transfer of &#x0005b;14C&#x0005d;phosphatidylcholine between liposomes and human plasma high density lipoprotein. Partial purification of a transfer-stimulating plasma factor using a rapid transfer assay.</article-title><source>Biochim Biophys Acta</source><volume>712</volume><fpage>444</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">7126618</pub-id></citation></ref><ref id="pone.0002255-Tall2"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tall</surname><given-names>AR</given-names></name><name><surname>Abreu</surname><given-names>E</given-names></name><name><surname>Shuman</surname><given-names>J</given-names></name></person-group><year>1983</year><article-title>Separation of a plasma phospholipid transfer protein from cholesterol ester/phospholipid exchange protein.</article-title><source>J Biol Chem</source><volume>258</volume><fpage>2174</fpage><lpage>2180</lpage><pub-id pub-id-type="pmid">6822552</pub-id></citation></ref><ref id="pone.0002255-Albers1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Albers</surname><given-names>JJ</given-names></name><name><surname>Cheung</surname><given-names>MC</given-names></name></person-group><year>2004</year><article-title>Emerging roles for phospholipid transfer protein in lipid and lipoprotein metabolism.</article-title><source>Curr Opin Lipidol</source><volume>15</volume><fpage>255</fpage><lpage>260</lpage><pub-id pub-id-type="pmid">15166780</pub-id></citation></ref><ref id="pone.0002255-Kostner1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kostner</surname><given-names>GM</given-names></name><name><surname>Oettl</surname><given-names>K</given-names></name><name><surname>Jauhiainen</surname><given-names>M</given-names></name><name><surname>Ehnholm</surname><given-names>C</given-names></name><name><surname>Esterbauer</surname><given-names>H</given-names></name><etal/></person-group><year>1995</year><article-title>Human plasma phospholipid transfer protein accelerates exchange/transfer of alpha-tocopherol between lipoproteins and cells.</article-title><source>Biochem J</source><volume>305</volume><fpage>659</fpage><lpage>667</lpage><pub-id pub-id-type="pmid">7832785</pub-id></citation></ref><ref id="pone.0002255-Tu1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tu</surname><given-names>AY</given-names></name><name><surname>Nishida</surname><given-names>HI</given-names></name><name><surname>Nishida</surname><given-names>T</given-names></name></person-group><year>1993</year><article-title>High density lipoprotein conversion mediated by human plasma phospholipid transfer protein.</article-title><source>J Biol Chem</source><volume>268</volume><fpage>23098</fpage><lpage>23105</lpage><pub-id pub-id-type="pmid">8226827</pub-id></citation></ref><ref id="pone.0002255-Jauhiainen1"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jauhiainen</surname><given-names>M</given-names></name><name><surname>Metso</surname><given-names>J</given-names></name><name><surname>Pahlman</surname><given-names>R</given-names></name><name><surname>Blomqvist</surname><given-names>S</given-names></name><name><surname>van Tol</surname><given-names>A</given-names></name><etal/></person-group><year>1993</year><article-title>Human plasma phospholipid transfer protein causes high density lipoprotein conversion.</article-title><source>J Biol Chem</source><volume>268</volume><fpage>4032</fpage><lpage>4036</lpage><pub-id pub-id-type="pmid">8440695</pub-id></citation></ref><ref id="pone.0002255-Assmann1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Assmann</surname><given-names>G</given-names></name><name><surname>Gotto</surname><given-names>AM</given-names><suffix>Jr</suffix></name></person-group><year>2004</year><article-title>HDL cholesterol and protective factors in atherosclerosis.</article-title><source>Circulation</source><volume>109</volume><fpage>III8</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">15198960</pub-id></citation></ref><ref id="pone.0002255-Ansell1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ansell</surname><given-names>BJ</given-names></name><name><surname>Navab</surname><given-names>M</given-names></name><name><surname>Watson</surname><given-names>KE</given-names></name><name><surname>Fonarow</surname><given-names>GC</given-names></name><name><surname>Fogelman</surname><given-names>AM</given-names></name></person-group><year>2004</year><article-title>Anti-inflammatory properties of HDL.</article-title><source>Rev Endocr Metab Disord</source><volume>5</volume><fpage>351</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">15486468</pub-id></citation></ref><ref id="pone.0002255-Barter1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barter</surname><given-names>PJ</given-names></name><name><surname>Nicholls</surname><given-names>S</given-names></name><name><surname>Rye</surname><given-names>KA</given-names></name><name><surname>Anantharamaiah</surname><given-names>GM</given-names></name><name><surname>Navab</surname><given-names>M</given-names></name><etal/></person-group><year>2004</year><article-title>Antiinflammatory properties of HDL.</article-title><source>Circ Res</source><volume>95</volume><fpage>764</fpage><lpage>772</lpage><pub-id pub-id-type="pmid">15486323</pub-id></citation></ref><ref id="pone.0002255-Huuskonen1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huuskonen</surname><given-names>J</given-names></name><name><surname>Olkkonen</surname><given-names>VM</given-names></name><name><surname>Jauhiainen</surname><given-names>M</given-names></name><name><surname>Ehnholm</surname><given-names>C</given-names></name></person-group><year>2001</year><article-title>The impact of phospholipid transfer protein (PLTP) on HDL metabolism.</article-title><source>Atherosclerosis</source><volume>155</volume><fpage>269</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">11254896</pub-id></citation></ref><ref id="pone.0002255-vanTol1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Tol</surname><given-names>A</given-names></name></person-group><year>2002</year><article-title>Phospholipid transfer protein.</article-title><source>Curr Opin Lipidol</source><volume>13</volume><fpage>135</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">11891415</pub-id></citation></ref><ref id="pone.0002255-Jiang1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>XC</given-names></name><name><surname>Bruce</surname><given-names>C</given-names></name><name><surname>Mar</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>M</given-names></name><name><surname>Ji</surname><given-names>Y</given-names></name><etal/></person-group><year>1999</year><article-title>Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels.</article-title><source>J Clin Invest</source><volume>103</volume><fpage>907</fpage><lpage>914</lpage><pub-id pub-id-type="pmid">10079112</pub-id></citation></ref><ref id="pone.0002255-vanHaperen1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Haperen</surname><given-names>R</given-names></name><name><surname>van Tol</surname><given-names>A</given-names></name><name><surname>Vermeulen</surname><given-names>P</given-names></name><name><surname>Jauhiainen</surname><given-names>M</given-names></name><name><surname>van Gent</surname><given-names>T</given-names></name><etal/></person-group><year>2000</year><article-title>Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice.</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>20</volume><fpage>1082</fpage><lpage>1088</lpage><pub-id pub-id-type="pmid">10764677</pub-id></citation></ref><ref id="pone.0002255-Fielding1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fielding</surname><given-names>CJ</given-names></name><name><surname>Fielding</surname><given-names>PE</given-names></name></person-group><year>2001</year><article-title>Cellular cholesterol efflux.</article-title><source>Biochim Biophys Acta</source><volume>1533</volume><fpage>175</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">11731329</pub-id></citation></ref><ref id="pone.0002255-Jiang2"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>XC</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Qiao</surname><given-names>C</given-names></name><name><surname>Kawano</surname><given-names>K</given-names></name><name><surname>Lin</surname><given-names>M</given-names></name><etal/></person-group><year>2001</year><article-title>Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency.</article-title><source>Nat Med</source><volume>7</volume><fpage>847</fpage><lpage>852</lpage><pub-id pub-id-type="pmid">11433351</pub-id></citation></ref><ref id="pone.0002255-VanHaperen1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Haperen</surname><given-names>R</given-names></name><name><surname>Van Tol</surname><given-names>A</given-names></name><name><surname>Van Gent</surname><given-names>T</given-names></name><name><surname>Scheek</surname><given-names>L</given-names></name><name><surname>Visser</surname><given-names>P</given-names></name><etal/></person-group><year>2002</year><article-title>Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein.</article-title><source>J Biol Chem</source><volume>277</volume><fpage>48938</fpage><lpage>48943</lpage><pub-id pub-id-type="pmid">12372822</pub-id></citation></ref><ref id="pone.0002255-Lie1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lie</surname><given-names>J</given-names></name><name><surname>De Crom</surname><given-names>R</given-names></name><name><surname>Van Gent</surname><given-names>T</given-names></name><name><surname>Van Haperen</surname><given-names>R</given-names></name><name><surname>Scheek</surname><given-names>L</given-names></name><etal/></person-group><year>2002</year><article-title>Elevation of plasma phospholipid transfer protein in transgenic mice increases VLDL secretion.</article-title><source>J Lipid Res</source><volume>43</volume><fpage>1875</fpage><lpage>1880</lpage><pub-id pub-id-type="pmid">12401886</pub-id></citation></ref><ref id="pone.0002255-Jiang3"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>XC</given-names></name><name><surname>Tall</surname><given-names>AR</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>M</given-names></name><name><surname>Schneider</surname><given-names>M</given-names></name><etal/></person-group><year>2002</year><article-title>Phospholipid transfer protein deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E. J Biol Chem</article-title><volume>277</volume><fpage>31850</fpage><lpage>31856</lpage></citation></ref><ref id="pone.0002255-Day1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Day</surname><given-names>JR</given-names></name><name><surname>Albers</surname><given-names>JJ</given-names></name><name><surname>Lofton-Day</surname><given-names>CE</given-names></name><name><surname>Gilbert</surname><given-names>TL</given-names></name><name><surname>Ching</surname><given-names>AF</given-names></name><etal/></person-group><year>1994</year><article-title>Complete cDNA encoding human phospholipid transfer protein from human endothelial cells.</article-title><source>J Biol Chem</source><volume>269</volume><fpage>9388</fpage><lpage>9391</lpage><pub-id pub-id-type="pmid">8132678</pub-id></citation></ref><ref id="pone.0002255-Albers2"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Albers</surname><given-names>JJ</given-names></name><name><surname>Wolfbauer</surname><given-names>G</given-names></name><name><surname>Cheung</surname><given-names>MC</given-names></name><name><surname>Day</surname><given-names>JR</given-names></name><name><surname>Ching</surname><given-names>AF</given-names></name><etal/></person-group><year>1995</year><article-title>Functional expression of human and mouse plasma phospholipid transfer protein: effect of recombinant and plasma PLTP on HDL subspecies.</article-title><source>Biochim Biophys Acta</source><volume>1258</volume><fpage>27</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">7654777</pub-id></citation></ref><ref id="pone.0002255-Laffitte1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laffitte</surname><given-names>BA</given-names></name><name><surname>Joseph</surname><given-names>SB</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Castrillo</surname><given-names>A</given-names></name><name><surname>Repa</surname><given-names>J</given-names></name><etal/></person-group><year>2003</year><article-title>The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions.</article-title><source>Mol Cell Biol</source><volume>23</volume><fpage>2182</fpage><lpage>2191</lpage><pub-id pub-id-type="pmid">12612088</pub-id></citation></ref><ref id="pone.0002255-OBrien1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Brien</surname><given-names>KD</given-names></name><name><surname>Vuletic</surname><given-names>S</given-names></name><name><surname>McDonald</surname><given-names>TO</given-names></name><name><surname>Wolfbauer</surname><given-names>G</given-names></name><name><surname>Lewis</surname><given-names>K</given-names></name><etal/></person-group><year>2003</year><article-title>Cell-Associated and Extracellular Phospholipid Transfer Protein in Human Coronary Atherosclerosis.</article-title><source>Circulation</source></citation></ref><ref id="pone.0002255-Okabe1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Okabe</surname><given-names>M</given-names></name><name><surname>Ikawa</surname><given-names>M</given-names></name><name><surname>Kominami</surname><given-names>K</given-names></name><name><surname>Nakanishi</surname><given-names>T</given-names></name><name><surname>Nishimune</surname><given-names>Y</given-names></name></person-group><year>1997</year><article-title>&#x02018;Green mice&#x02019; as a source of ubiquitous green cells.</article-title><source>FEBS Lett</source><volume>407</volume><fpage>313</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">9175875</pub-id></citation></ref><ref id="pone.0002255-Peeters1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peeters</surname><given-names>M</given-names></name><name><surname>Ling</surname><given-names>KW</given-names></name><name><surname>Oziemlak</surname><given-names>A</given-names></name><name><surname>Robin</surname><given-names>C</given-names></name><name><surname>Dzierzak</surname><given-names>E</given-names></name></person-group><year>2005</year><article-title>Multipotential hematopoietic progenitor cells from embryos developed in vitro engraft unconditioned W41/W41 neonatal miceB.</article-title><source>Haematologica</source><volume>90</volume><fpage>734</fpage><lpage>739</lpage><pub-id pub-id-type="pmid">15951285</pub-id></citation></ref><ref id="pone.0002255-vanHaperen2"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Haperen</surname><given-names>R</given-names></name><name><surname>de Waard</surname><given-names>M</given-names></name><name><surname>van Deel</surname><given-names>E</given-names></name><name><surname>Mees</surname><given-names>B</given-names></name><name><surname>Kutryk</surname><given-names>M</given-names></name><etal/></person-group><year>2002</year><article-title>Reduction of blood pressure, plasma cholesterol, and atherosclerosis by elevated endothelial nitric oxide.</article-title><source>J Biol Chem</source><volume>277</volume><fpage>48803</fpage><lpage>48807</lpage><pub-id pub-id-type="pmid">12364322</pub-id></citation></ref><ref id="pone.0002255-Bouma1"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bouma</surname><given-names>G</given-names></name><name><surname>Nikolic</surname><given-names>T</given-names></name><name><surname>Coppens</surname><given-names>JM</given-names></name><name><surname>van Helden-Meeuwsen</surname><given-names>CG</given-names></name><name><surname>Leenen</surname><given-names>PJ</given-names></name><etal/></person-group><year>2005</year><article-title>NOD mice have a severely impaired ability to recruit leukocytes into sites of inflammation.</article-title><source>Eur J Immunol</source><volume>35</volume><fpage>225</fpage><lpage>235</lpage><pub-id pub-id-type="pmid">15593124</pub-id></citation></ref><ref id="pone.0002255-Rothblat1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rothblat</surname><given-names>GH</given-names></name><name><surname>Bamberger</surname><given-names>M</given-names></name><name><surname>Phillips</surname><given-names>MC</given-names></name></person-group><year>1986</year><article-title>Reverse cholesterol transport.</article-title><source>Methods Enzymol</source><volume>129</volume><fpage>628</fpage><lpage>644</lpage><pub-id pub-id-type="pmid">3523160</pub-id></citation></ref><ref id="pone.0002255-Basu1"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Basu</surname><given-names>SK</given-names></name><name><surname>Goldstein</surname><given-names>JL</given-names></name><name><surname>Anderson</surname><given-names>GW</given-names></name><name><surname>Brown</surname><given-names>MS</given-names></name></person-group><year>1976</year><article-title>Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts.</article-title><source>Proc Natl Acad Sci U S A</source><volume>73</volume><fpage>3178</fpage><lpage>3182</lpage><pub-id pub-id-type="pmid">184464</pub-id></citation></ref><ref id="pone.0002255-Lowry1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lowry</surname><given-names>OH</given-names></name><name><surname>Rosebrough</surname><given-names>NJ</given-names></name><name><surname>Farr</surname><given-names>AL</given-names></name><name><surname>Randall</surname><given-names>RJ</given-names></name></person-group><year>1951</year><article-title>Protein measurement with the Folin phenol reagent.</article-title><source>J Biol Chem</source><volume>193</volume><fpage>265</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">14907713</pub-id></citation></ref><ref id="pone.0002255-Lie2"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lie</surname><given-names>J</given-names></name><name><surname>De Crom</surname><given-names>R</given-names></name><name><surname>Van Gent</surname><given-names>T</given-names></name><name><surname>Van Haperen</surname><given-names>R</given-names></name><name><surname>Scheek</surname><given-names>L</given-names></name><etal/></person-group><year>2004</year><article-title>Elevation of plasma phospholipid transfer protein increases the risk of atherosclerosis in spite of lowering apolipoprotein B containing lipoproteins.</article-title><source>J Lipid Res</source><volume>45</volume><fpage>805</fpage><lpage>811</lpage><pub-id pub-id-type="pmid">14993244</pub-id></citation></ref><ref id="pone.0002255-Desrumaux1"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Desrumaux</surname><given-names>CM</given-names></name><name><surname>Mak</surname><given-names>PA</given-names></name><name><surname>Boisvert</surname><given-names>WA</given-names></name><name><surname>Masson</surname><given-names>D</given-names></name><name><surname>Stupack</surname><given-names>D</given-names></name><etal/></person-group><year>2003</year><article-title>Phospholipid transfer protein is present in human atherosclerotic lesions and is expressed by macrophages and foam cells.</article-title><source>J Lipid Res</source><volume>44</volume><fpage>1453</fpage><lpage>1461</lpage><pub-id pub-id-type="pmid">12730304</pub-id></citation></ref><ref id="pone.0002255-Stein1"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>O</given-names></name><name><surname>Stein</surname><given-names>Y</given-names></name></person-group><year>2005</year><article-title>Lipid transfer proteins (LTP) and atherosclerosis.</article-title><source>Atherosclerosis</source><volume>178</volume><fpage>217</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">15694928</pub-id></citation></ref><ref id="pone.0002255-Colhoun1"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Colhoun</surname><given-names>HM</given-names></name><name><surname>Taskinen</surname><given-names>MR</given-names></name><name><surname>Otvos</surname><given-names>JD</given-names></name><name><surname>Van Den Berg</surname><given-names>P</given-names></name><name><surname>O'Connor</surname><given-names>J</given-names></name><etal/></person-group><year>2002</year><article-title>Relationship of Phospholipid Transfer Protein Activity to HDL and Apolipoprotein B-Containing Lipoproteins in Subjects With and Without Type 1 Diabetes.</article-title><source>Diabetes</source><volume>51</volume><fpage>3300</fpage><lpage>3305</lpage><pub-id pub-id-type="pmid">12401722</pub-id></citation></ref><ref id="pone.0002255-Riemens1"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Riemens</surname><given-names>SC</given-names></name><name><surname>van Tol</surname><given-names>A</given-names></name><name><surname>Sluiter</surname><given-names>WJ</given-names></name><name><surname>Dullaart</surname><given-names>RP</given-names></name></person-group><year>1998</year><article-title>Plasma phospholipid transfer protein activity is related to insulin resistance: impaired acute lowering by insulin in obese Type II diabetic patients.</article-title><source>Diabetologia</source><volume>41</volume><fpage>929</fpage><lpage>934</lpage><pub-id pub-id-type="pmid">9726595</pub-id></citation></ref><ref id="pone.0002255-Desrumaux2"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Desrumaux</surname><given-names>C</given-names></name><name><surname>Athias</surname><given-names>A</given-names></name><name><surname>Bessede</surname><given-names>G</given-names></name><name><surname>Verges</surname><given-names>B</given-names></name><name><surname>Farnier</surname><given-names>M</given-names></name><etal/></person-group><year>1999</year><article-title>Mass concentration of plasma phospholipid transfer protein in normolipidemic, type IIa hyperlipidemic, type IIb hyperlipidemic, and non-insulin-dependent diabetic subjects as measured by a specific ELISA.</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>19</volume><fpage>266</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">9974406</pub-id></citation></ref><ref id="pone.0002255-Dullaart1"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dullaart</surname><given-names>RP</given-names></name><name><surname>Sluiter</surname><given-names>WJ</given-names></name><name><surname>Dikkeschei</surname><given-names>LD</given-names></name><name><surname>Hoogenberg</surname><given-names>K</given-names></name><name><surname>Van Tol</surname><given-names>A</given-names></name></person-group><year>1994</year><article-title>Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism.</article-title><source>Eur J Clin Invest</source><volume>24</volume><fpage>188</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">8033953</pub-id></citation></ref><ref id="pone.0002255-Cheung1"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>MC</given-names></name><name><surname>Knopp</surname><given-names>RH</given-names></name><name><surname>Retzlaff</surname><given-names>B</given-names></name><name><surname>Kennedy</surname><given-names>H</given-names></name><name><surname>Wolfbauer</surname><given-names>G</given-names></name><etal/></person-group><year>2002</year><article-title>Association of plasma phospholipid transfer protein activity with IDL and buoyant LDL: impact of gender and adiposity.</article-title><source>Biochim Biophys Acta</source><volume>1587</volume><fpage>53</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">12009424</pub-id></citation></ref><ref id="pone.0002255-Kaser1"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaser</surname><given-names>S</given-names></name><name><surname>Sandhofer</surname><given-names>A</given-names></name><name><surname>Foger</surname><given-names>B</given-names></name><name><surname>Ebenbichler</surname><given-names>CF</given-names></name><name><surname>Igelseder</surname><given-names>B</given-names></name><etal/></person-group><year>2001</year><article-title>Influence of obesity and insulin sensitivity on phospholipid transfer protein activity.</article-title><source>Diabetologia</source><volume>44</volume><fpage>1111</fpage><lpage>1117</lpage><pub-id pub-id-type="pmid">11596664</pub-id></citation></ref><ref id="pone.0002255-Murdoch1"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murdoch</surname><given-names>SJ</given-names></name><name><surname>Carr</surname><given-names>MC</given-names></name><name><surname>Hokanson</surname><given-names>JE</given-names></name><name><surname>Brunzell</surname><given-names>JD</given-names></name><name><surname>Albers</surname><given-names>JJ</given-names></name></person-group><year>2000</year><article-title>PLTP activity in premenopausal women. Relationship with lipoprotein lipase, HDL, LDL, body fat, and insulin resistance.</article-title><source>J Lipid Res</source><volume>41</volume><fpage>237</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">10681407</pub-id></citation></ref><ref id="pone.0002255-Murdoch2"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murdoch</surname><given-names>SJ</given-names></name><name><surname>Kahn</surname><given-names>SE</given-names></name><name><surname>Albers</surname><given-names>JJ</given-names></name><name><surname>Brunzell</surname><given-names>JD</given-names></name><name><surname>Purnell</surname><given-names>JQ</given-names></name></person-group><year>2003</year><article-title>PLTP activity decreases with weight loss: changes in PLTP are associated with changes in subcutaneous fat and FFA but not IAF or insulin sensitivity.</article-title><source>J Lipid Res</source><volume>44</volume><fpage>1705</fpage><lpage>1712</lpage><pub-id pub-id-type="pmid">12837855</pub-id></citation></ref><ref id="pone.0002255-deVries1"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Vries</surname><given-names>R</given-names></name><name><surname>Dallinga-Thie</surname><given-names>GM</given-names></name><name><surname>Smit</surname><given-names>AJ</given-names></name><name><surname>Wolffenbuttel</surname><given-names>BH</given-names></name><name><surname>van Tol</surname><given-names>A</given-names></name><etal/></person-group><year>2006</year><article-title>Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus.</article-title><source>Diabetologia</source><volume>49</volume><fpage>398</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">16374627</pub-id></citation></ref><ref id="pone.0002255-Foger1"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Foger</surname><given-names>B</given-names></name><name><surname>Santamarina-Fojo</surname><given-names>S</given-names></name><name><surname>Shamburek</surname><given-names>RD</given-names></name><name><surname>Parrot</surname><given-names>CL</given-names></name><name><surname>Talley</surname><given-names>GD</given-names></name><etal/></person-group><year>1997</year><article-title>Plasma phospholipid transfer protein. Adenovirus-mediated overexpression in mice leads to decreased plasma high density lipoprotein (HDL) and enhanced hepatic uptake of phospholipids and cholesteryl esters from HDL.</article-title><source>J Biol Chem</source><volume>272</volume><fpage>27393</fpage><lpage>27400</lpage><pub-id pub-id-type="pmid">9341191</pub-id></citation></ref><ref id="pone.0002255-Ehnholm1"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ehnholm</surname><given-names>S</given-names></name><name><surname>van Dijk</surname><given-names>KW</given-names></name><name><surname>van 't Hof</surname><given-names>B</given-names></name><name><surname>van der Zee</surname><given-names>A</given-names></name><name><surname>Olkkonen</surname><given-names>VM</given-names></name><etal/></person-group><year>1998</year><article-title>Adenovirus mediated overexpression of human phospholipid transfer protein alters plasma HDL levels in mice.</article-title><source>J Lipid Res</source><volume>39</volume><fpage>1248</fpage><lpage>1253</lpage><pub-id pub-id-type="pmid">9643356</pub-id></citation></ref><ref id="pone.0002255-Yan1"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>D</given-names></name><name><surname>Navab</surname><given-names>M</given-names></name><name><surname>Bruce</surname><given-names>C</given-names></name><name><surname>Fogelman</surname><given-names>AM</given-names></name><name><surname>Jiang</surname><given-names>XC</given-names></name></person-group><year>2004</year><article-title>PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity.</article-title><source>J Lipid Res</source><volume>45</volume><fpage>1852</fpage><lpage>1858</lpage><pub-id pub-id-type="pmid">15258196</pub-id></citation></ref><ref id="pone.0002255-Schlitt1"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schlitt</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>D</given-names></name><name><surname>Mondragon-Escorpizo</surname><given-names>M</given-names></name><name><surname>Norin</surname><given-names>AJ</given-names></name><etal/></person-group><year>2005</year><article-title>Anti-inflammatory effects of phospholipid transfer protein (PLTP) deficiency in mice.</article-title><source>Biochim Biophys Acta</source><volume>1733</volume><fpage>187</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">15863365</pub-id></citation></ref><ref id="pone.0002255-Cheung2"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>MC</given-names></name><name><surname>Brown</surname><given-names>BG</given-names></name><name><surname>Marino Larsen</surname><given-names>EK</given-names></name><name><surname>Frutkin</surname><given-names>AD</given-names></name><name><surname>O'Brien</surname><given-names>KD</given-names></name><etal/></person-group><year>2005</year><article-title>Phospholipid transfer protein activity is associated with inflammatory markers in patients with cardiovascular disease.</article-title><source>Biochim Biophys Acta</source><volume>1762</volume><fpage>131</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">16216472</pub-id></citation></ref><ref id="pone.0002255-Karkkainen1"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karkkainen</surname><given-names>M</given-names></name><name><surname>Oka</surname><given-names>T</given-names></name><name><surname>Olkkonen</surname><given-names>VM</given-names></name><name><surname>Metso</surname><given-names>J</given-names></name><name><surname>Hattori</surname><given-names>H</given-names></name><etal/></person-group><year>2002</year><article-title>Isolation and partial characterization of the inactive and active forms of human plasma phospholipid transfer protein (PLTP).</article-title><source>J Biol Chem</source><volume>277</volume><fpage>15413</fpage><lpage>15418</lpage><pub-id pub-id-type="pmid">11854286</pub-id></citation></ref><ref id="pone.0002255-Valenta1"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Valenta</surname><given-names>DT</given-names></name><name><surname>Ogier</surname><given-names>N</given-names></name><name><surname>Bradshaw</surname><given-names>G</given-names></name><name><surname>Black</surname><given-names>AS</given-names></name><name><surname>Bonnet</surname><given-names>DJ</given-names></name><etal/></person-group><year>2006</year><article-title>Atheroprotective Potential of Macrophage-Derived Phospholipid Transfer Protein in Low-Density Lipoprotein Receptor-Deficient Mice Is Overcome by Apolipoprotein AI Overexpression.</article-title><source>Arterioscler Thromb Vasc Biol</source></citation></ref><ref id="pone.0002255-Vikstedt1"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vikstedt</surname><given-names>R</given-names></name><name><surname>Ye</surname><given-names>D</given-names></name><name><surname>Metso</surname><given-names>J</given-names></name><name><surname>Hildebrand</surname><given-names>RB</given-names></name><name><surname>Van Berkel</surname><given-names>TJ</given-names></name><etal/></person-group><year>2007</year><article-title>Macrophage phospholipid transfer protein contributes significantly to total plasma phospholipid transfer activity and its deficiency leads to diminished atherosclerotic lesion development.</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>27</volume><fpage>578</fpage><lpage>586</lpage><pub-id pub-id-type="pmid">17170377</pub-id></citation></ref><ref id="pone.0002255-Valenta2"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Valenta</surname><given-names>DT</given-names></name><name><surname>Bulgrien</surname><given-names>JJ</given-names></name><name><surname>Bonnet</surname><given-names>DJ</given-names></name><name><surname>Curtiss</surname><given-names>LK</given-names></name></person-group><year>2008</year><article-title>Macrophage PLTP is atheroprotective in LDLr-deficient mice with systemic PLTP deficiency.</article-title><source>J Lipid Res</source><volume>49</volume><fpage>24</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">17928634</pub-id></citation></ref><ref id="pone.0002255-Lie3"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lie</surname><given-names>J</given-names></name><name><surname>Moerland</surname><given-names>M</given-names></name><name><surname>van Gent</surname><given-names>T</given-names></name><name><surname>van Haperen</surname><given-names>R</given-names></name><name><surname>Scheek</surname><given-names>L</given-names></name><etal/></person-group><year>2006</year><article-title>Sex differences in atherosclerosis in mice with elevated phospholipid transfer protein activity are related to decreased plasma high density lipoproteins and not to increased production of triglycerides.</article-title><source>Biochim Biophys Acta</source><volume>1761</volume><fpage>1070</fpage><lpage>1077</lpage><pub-id pub-id-type="pmid">16935026</pub-id></citation></ref><ref id="pone.0002255-Jordan1"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>CT</given-names></name><name><surname>Lemischka</surname><given-names>IR</given-names></name></person-group><year>1990</year><article-title>Clonal and systemic analysis of long-term hematopoiesis in the mouse.</article-title><source>Genes Dev</source><volume>4</volume><fpage>220</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">1970972</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>Part of this work was supported by Zorgonderzoek Nederland Medische Wetenschappen-the Netherlands Organisation for Health Research and Development (910-31-806).</p></fn></fn-group></back></article> 